Genentech promotes two of its own to fill corporate PR vacancies

SAN FRANCISCO: Bay Area biotech giant Genentech has promoted from within to fill two key vacancies in its corporate communications department.

SAN FRANCISCO: Bay Area biotech giant Genentech has promoted from within to fill two key vacancies in its corporate communications department.

SAN FRANCISCO: Bay Area biotech giant Genentech has promoted from

within to fill two key vacancies in its corporate communications

department.



The San Francisco-based drug company, currently in the midst of an IPO

(parent company Roche is spinning off 15% of Genentech stock) last week

promoted senior director of corporate communications Laura Leber to VP

of corporate communications, while senior corporate communications

manager Marie Kennedy moved up to associate director for corporate

communications.



Leber is responsible for all standard corporate PR, including

communications relating to corporate earnings, advocacy relations,

employee communications and community relations. She reports to EVP/CFO

Louis Lavigny Jr.



Kennedy will oversee all of Genentech’s brand PR for therapeutic

products, effectively replacing Paul Laland, who left in July to head up

a new biotech/medical technology division for GCI/San Francisco (PRWeek,

July 26).



Kennedy’s previous post, in which she oversaw all corporate

communications and investor relations, is still vacant. The company has

not announced a timetable for replacing her.



Genentech is considered among the leading innovators in the biotech

sector.



Among its seven products manufactured and marketed in the US is the

Pulmozyme Inhalation Solution, the first therapeutic approach for

treating cystic fibrosis in 30 years.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in